Drugs and Devices

FDA approves Imbruvica to treat chronic lymphocytic leukemia

On Feb. 13, the U.S. Food and Drug Administration (FDA) expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia patients who have received at least one previous therapy.
Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares